JAMDA
Volume 8, Issue 4 , Pages 243-247 , May 2007

The Use of a Cholinesterase Inhibitor Review Committee in Long-Term Care

  • Joyce Lee, MD, BScPhm

      Affiliations

    • Division of Geriatric Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Canada
    • Solidage, McGill/Université de Montréal Research Group on Services for Older Persons, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada
    • Department of Family and Community Medicine, University of Toronto, Toronto, Canada
    • Corresponding Author InformationAddress correspondence to Joyce Lee, MD, BScPhm, North York General Hospital, 4001 Leslie Street, Toronto, Ontario, M2K 1E1, Canada.
    • ,
  • Johanne Monette, MD, MSc

      Affiliations

    • Division of Geriatric Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Canada
    • Solidage, McGill/Université de Montréal Research Group on Services for Older Persons, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada
    • ,
  • Nadia Sourial, MSc

      Affiliations

    • Solidage, McGill/Université de Montréal Research Group on Services for Older Persons, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada
    • ,
  • Michele Monette, OT, MSc

      Affiliations

    • Solidage, McGill/Université de Montréal Research Group on Services for Older Persons, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada
    • Maimonides Geriatric Centre, McGill University, Montreal, Canada.
    • ,
  • Howard Bergman, MD

      Affiliations

    • Division of Geriatric Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Canada
    • Solidage, McGill/Université de Montréal Research Group on Services for Older Persons, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada

References 

  1. Patterson C, Gauthier S, Bergman H, et al. The recognition, assessment and management of dementing disorders: Conclusions from the Canadian Consensus Conference on Dementia. Can J Neurol Sci. 2001;28(Suppl 1):S3–S16
  2. Guidelines abstracted from the American Academy of Neurology’s Dementia Guidelines for Early Detection, Diagnosis, and Management of Dementia. J Am Geriatr Soc. 2003;51:869–873
  3. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) & memantine for the treatment of Alzheimer disease, NICE. 2006;Available at: http://www.nice.org.uk/. Accessed December 9, 2006.
  4. Hebert R, Dubois MF, Wolfson C, Chambers L, Cohen C. Factors associated with long-term institutionalization of older people with dementia: Data from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci. 2001;56(11):M693–M699
  5. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590–1599
  6. Khang P, Weintraub N, Espinoza RT. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer’s dementia in long-term care: Are the data relevant and available?. J Am Med Dir Assoc. 2004;5:249–255
  7. Holroyd S. Managing dementia in long-term care settings. Clin Geriatr Med. 2004;20:83–92
  8. Mills EJ, Chow TW. Randomized controlled trials in long-term care residents with dementia: A systematic review. J Am Med Dir Assoc. 2003;4:302–307
  9. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: Double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367:1057–1065
  10. Vantelon C, Gilbert S, Kerneis S, Wolmark Y, Legrain S, Kergoat MJ. [Cholinesterase inhibitor therapy in long term care settings]. Rev Med Interne. 2006;27:588–594French
  11. Rainer M, Mucke HA, Kruger-Rainer C, Kraxberger E, Haushofer M, Jellinger KA. Cognitive relapse after discontinuation of drug therapy in Alzheimer’s disease: Cholinesterase inhibitors versus nootropics. J Neural Transm. 2001;108:1327–1333
  12. Singh S, Dudley C. Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry. 2003;18:282–284
  13. Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? (An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia). Int J Geriatr Psychiatry. 2003;18:988–993
  14. Regie de l’assurance maladie de Quebec. Liste des medicaments d’exception et des indications reconnues pour leur paiment. RAMQ, 2006. Available at: http://www.ramq.gouv.qc.ca/fr/professionnels/listmed/pdf/modification/annexe_9.pdf. Accessed June 6, 2006.
  15. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  16. Bellelli G, Frisoni GB, Bianchetti A, Trabucchi M. The Bedford Alzheimer Nursing Severity scale for the severely demented: Validation study. Alzheimer Dis Assoc Disord. 1997;11:71–77
  17. Auer SR, Monteiro IM, Reisberg B. The Empirical Behavioral Pathology in Alzheimer’s Disease (E-BEHAVE-AD) Rating Scale. Int Psychogeriatr. 1996;8:247–266
  18. Ables AZ, Baughman OL. Antidepressants: Update on new agents and indications. Am Fam Physician. 2003;67:547–554
  19. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001;24:183–197
  20. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:85–102
  21. O’Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66(Suppl 2):28–33
  22. Chouinard G. Issues in the clinical use of benzodiazepines: Potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(Suppl 5):7–12

 Funding was provided by the Division of Geriatrics, McGill University. There is no conflict of interest to declare.

PII: S1525-8610(07)00171-5

doi: 10.1016/j.jamda.2007.02.007

JAMDA
Volume 8, Issue 4 , Pages 243-247 , May 2007

Article Tools

* Image Usage & Resolution